- Current report filing (8-K)
September 29 2010 - 6:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): September 29, 2010
SHENGTAI
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
000-51312
|
|
54-2155579
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
Changda
Road East
Development
District, Changle County
Shandong,
262400
The
People’s Republic of China
(Address
of principal executive offices, including zip code)
(86)
536-6295802
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02 Results of Operations and Financial
Conditions
On
September 29, 2010, Shengtai Pharmaceutical, Inc. (the “Company”) issued a press
release announcing its results for the year ended June 30, 2010. The
Company will host a management conference call to discuss the results at 5:00
a.m. (Pacific)/8:00 a.m. (Eastern)/8:00 p.m. (Shandong/Hong Kong) on Thursday,
September 30, 2010. The press release is attached as Exhibit 99.1 to this
report on Form 8-K.
The
information in this Current Report, including Exhibit 99.1, shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or incorporated subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities
Act of 1933, as amended (the “Securities Act”), and shall not be incorporated by
reference in any registration statement or other document filed under the
Securities Act or the Exchange Act, whether made before or after the date
hereof, regardless of any general incorporation language in such filings, except
as shall be expressly set forth by specific reference in such a
filing.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
Exhibit
No
|
|
Description
|
99.1
|
|
Press
Release of Shengtai Pharmaceutical, Inc., dated September 29,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
SHENGTAI
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
Dated:
September 29, 2010
|
By:
|
/s/
Qingtai Liu
|
|
|
|
Name:
Qingtai Liu
|
|
|
|
Title:
Chief Executive Officer
|
|
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From May 2024 to Jun 2024
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Jun 2023 to Jun 2024